DE102010019438A1 - Composition, useful e.g. foodstuff for dietary treatment of stress-, nutritional- or endogenously-induced disorders of serotonin metabolism, comprises e.g. tryptophan, pyridoxine, magnesium, iron, carbohydrates and royal jelly - Google Patents

Abstract

Composition comprises (per 30 ml aqueous solution): tryptophan (300-600 mg), niacin (vitamin B3) (15-45 mg), pyridoxine (vitamin B6) (10-30 mg), folic acid (vitamin B9) (400-1200 mu g), cyanocobalamin (vitamin B12) (5-15 mu g), ascorbic acid (50-200 mg), magnesium (50-200 mg), iron(II) (2-5 mg), carbohydrates (10-20 g) and royal jelly (100-500 mg). An independent claimS is also included for a formulation comprising the composition. ACTIVITY : Anabolic; Tranquilizer; Metabolic. No biological data given. MECHANISM OF ACTION : None given.

Description

Technical field of the present invention

The present invention relates to a concentrated nutrient composition which stringently supports the pathway of natural central nervous system (CNS) serotonin synthesis and the use of this composition in a diet for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin -Stoffwechsels.

Background of the invention

In the modern meritocracy, individuals demand an ever greater degree of resilience and willingness to perform. Stress, mental fatigue and mental imbalance are often the inevitable consequences of this lifestyle and often lead to burn-out syndrome and depressive moods.

The desire to keep up with the increasing demands is increasingly coming to the fore. This is accompanied by the growth in the consumption of vitamin and mineral supplements, which has grown over the same period of time, which should help to make body and mind more resistant and more efficient. Newer foods promise to boost the immune system; Energy drinks also give consumers hope that they will be more efficient and concentrated at least in the short term.

However, the desire for increased performance, resilience, balance and positive mood now seems to be so dominant that the stress-prone man is even willing to higher risks through the use of psychotropic drugs, such as. As antidepressants, enter. It is not for nothing that pharmaceutical companies and the media have recently created word creations such as "brain boosters", "neuro-enhancement", "brain doping" and "cogniceuticals", often referring to psychotropic drugs for seriously ill patients, with sometimes not inconsiderable side effects.

The message seems to arrive, as a study published in 2009 by the German Employees' Health Insurance Fund (DAK) impressively shows: The study, which was carried out on 3,000 workers between 20 and 50 years, shows that 40% of respondents believe that psychotropic drugs for depression also increase the performance of healthy people. 20% believe that the benefits of such drugs are in proportion to their side effects. 5% already use psychotropic drugs to increase their performance; without a disease. Extrapolated this would be in Germany already 2 million workers ( DAK, (2009), Doping in the Office, www.presse.dak.de ). Undoubtedly a worrying and dangerous development against the background of side effects and the possible search risk.

This raises the question of how to bring about greater balance, more happiness and, above all, stress resistance in a gentler and more natural way in stress-afflicted people.

On the other hand, considering the stress metabolism on the one hand and the brain metabolism responsible for happiness and balance on the other hand, several aspects have to be considered. In the first approximation, two neurotransmitters are directly involved in the expression of sensations such as happiness and balance, and thus stress resistance. These are the neurotransmitters dopamine and serotonin. While dopamine is more likely to promote curiosity and an agitated sense of happiness, serotonin causes mood enhancement without agitation, as well as an inner balance with antidepressant effects. This is clearly shown by the anti-depressants of the SSRI class (Selected Serotonin Reuptake Inhibitors).

Thus, when it comes to supporting happiness, balance and stress resistance, the serotonin pathway rather than the dopamine pathway should be promoted. This raises the question of how this funding can be done without resorting to medicines. Dietary intake of serotonin is ruled out because serotonin can not cross the blood-brain barrier and thus can not reach its target sites in the CNS. The present invention is therefore based on the technical problem of providing a food which stringently supports the natural serotonin synthesis in the central nervous system (CNS). The solution of this object is achieved by providing the composition according to the invention and the embodiments characterized in the claims.

Summary of the invention

The composition of the invention comprises those nutrients in concentrated form which for the first time achieve a stringent natural serotonin synthesis in the central nervous system (CNS). However, as with cases of doping, the CNS is not forced into a metabolic pathway, but the CNS is supplied with the naturally occurring nutrients in such a way that the synthesis mechanisms are supported and a stringent serotonin Synthesis be enabled. The composition of the invention thus provides for an optimization of the natural serotonin metabolism and thus the natural serotonin synthesis in the CNS.

• [1] Zusammensetzung umfassend pro 30 ml wässriger Lösung:
• (a) Tryptophan: 300–600 mg;
• (b) Niacin (Vitamin B3): 15–45 mg;
• (c) Pyridoxin (Vitamin B6): 10–30 mg;
• (d) Folsäure (Vitamin B9): 400–1200 μg;
• (e) Cyanocobalamin (Vitamin B12): 5–15 μg;
• (f) Ascorbinsäure: 50–200 mg;
• (g) Magnesium: 50–200 mg;
• (h) Eisen(II): 2–5 mg;
• (i) Kohlehydrate: 10–20 g; und
• (j) Gelee Royal: 100–500 mg.
• [2] Zusammensetzung gemäß Ziffer [1], weiterhin umfassend pro 30 ml wässriger Lösung:
• (k) Koffein: 20–80 mg; und/oder
• (l) Zink: 5–20 mg.
• [3] Zusammensetzung gemäß Ziffer [1] oder [2], wobei die Kohlehydrate ausgewählt sind aus der Gruppe bestehend aus Monosacchariden, vorzugsweise Glukose, Fruktose, Galaktose, Xylose, und Ribose; Glukosepolymeren; Glukosesirup; Zuckeralkoholen; Malto-Dextrinen; Mannose; Fruktosesirup; Maissirup; Maltose; Saccharose; Glukose-enthaltenden Disacchariden, welche nicht Maltose und Saccharose sind, vorzugsweise ein Disaccharid ausgewählt aus der Gruppe bestehend aus Laktose, Palatinose, Trehalose, Leucrose und Isomaltose; Glukose-enthaltenden Oligosacchariden; und Glucose-enthaltenden Polysacchariden.
• [4] Formulierung umfassend die Zusammensetzung gemäß einer der Ziffern [1], [2] oder [3].
• [5] Verwendung der Zusammensetzung gemäß einer der Ziffern [1] bis [3] oder der Formulierung gemäß Ziffer [4] zur diätetischen Behandlung einer stress-, ernährungs- oder endogen-bedingten Störung des Serotonin-Stoffwechsels.
• [6] Verwendung gemäß Ziffer [5], wobei die stress-, ernährungs- oder endogen-bedingte Störung des Serotonin-Stoffwechsels eine stress-, ernährungs- oder endogen-bedingte Serotonin-Mangelerscheinung im ZNS ist.
• [7] Verwendung der Zusammensetzung gemäß einer der Ziffern [1] bis [3] oder der Formulierung gemäß Ziffer [4] als Zusatz zur Behandlung einer stress-, ernährungs- oder endogen-bedingten Störung des Serotonin-Stoffwechsels.
• [8] Getränk, ernährungsphysiologische Zubereitung, Nahrungsergänzungsmittel oder diätetisches Lebensmittel, umfassend die Zusammensetzung gemäß einer der Ziffern [1] bis [3] oder die Formulierung gemäß Ziffer [4].
• [9] Lebensmittel gemäß Ziffer [8], welches ein diätetisches Lebensmittel ist.
• [10] Lebensmittel gemäß Ziffer [9], welches ein diätetisches Lebensmittel für besondere medizinische Zwecke ist (ergänzende bilanzierte Diät).
• [11] Verwendung des Getränks, der ernährungsphysiologischen Zubereitung, des Nahrungsergänzungsmittels oder des Lebensmittels gemäß Ziffer [8] zur diätetischen Behandlung einer stress-, ernährungs- oder endogen-bedingten Störung des Serotonin-Stoffwechsels.
• [12] Verwendung gemäß Ziffer [11], wobei die stress-, ernährungs- oder endogen-bedingte Störung des Serotonin-Stoffwechsels eine stress-, ernährungs- oder endogen-bedingte Serotonin-Mangelerscheinung im ZNS ist.
• [13] Verwendung des Getränks, der ernährungsphysiologischen Zubereitung, des Nahrungsergänzungsmittels oder des Lebensmittels gemäß Ziffer [8] als Zusatz zur Behandlung einer stress-, ernährungs- oder endogen-bedingten Störung des Serotonin-Stoffwechsels.
• [14] Verwendung gemäß Ziffer [10], [11] oder [12], wobei das Lebensmittel ein diätetisches Lebensmittel ist.
• [15] Verwendung gemäß Ziffer [14], wobei das diätetische Lebensmittel ein diätetisches Lebensmittel für besondere medizinische Zwecke ist (ergänzende bilanzierte Diät).

The present invention provides:

• [1] Composition comprising per 30 ml of aqueous solution:
• (a) tryptophan: 300-600 mg;
• (b) Niacin (Vitamin B3): 15-45 mg;
• (c) pyridoxine (vitamin B6): 10-30 mg;
• (d) folic acid (vitamin B9): 400-1200 μg;
• (e) cyanocobalamin (vitamin B12): 5-15 μg;
• (f) ascorbic acid: 50-200 mg;
• (g) magnesium: 50-200 mg;
• (h) iron (II): 2-5 mg;
• (i) carbohydrates: 10-20 g; and
• (j) royal jelly: 100-500 mg.
• [2] Composition according to item [1], further comprising per 30 ml of aqueous solution:
• (k) caffeine: 20-80 mg; and or
• (I) Zinc: 5-20 mg.
• [3] The composition according to item [1] or [2], wherein the carbohydrates are selected from the group consisting of monosaccharides, preferably glucose, fructose, galactose, xylose, and ribose; Glucose polymers; Glucose syrup; Sugar alcohols; Malto-dextrins; mannose; Fructose syrup; Corn syrup; maltose; sucrose; Glucose-containing disaccharides which are not maltose and sucrose, preferably a disaccharide selected from the group consisting of lactose, palatinose, trehalose, leucrose and isomaltose; Glucose-containing oligosaccharides; and glucose-containing polysaccharides.
• [4] Formulation comprising the composition according to any of [1], [2] or [3].
• [5] Use of the composition according to any of [1] to [3] or the formulation according to [4] for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.
• [6] Use according to item [5], where the stress, nutrition or endogenous disorder of serotonin metabolism is a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.
• [7] Use of the composition according to any of [1] to [3] or the formulation according to [4] as an adjunct to the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.
• [8] A drink, nutritional preparation, dietary supplement or dietetic foodstuff comprising the composition according to any of [1] to [3] or the formulation according to [4].
• [9] Food according to item [8], which is a dietary food.
• [10] Food according to item [9], which is a dietary food for special medical purposes (supplementary balanced diet).
• [11] Use of the drink, nutritional preparation, nutritional supplement or foodstuff referred to in [8] for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.
• [12] Use according to item [11], wherein the stress, nutrition or endogenous disorder of serotonin metabolism is a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.
• [13] Use of the drink, nutritional or nutritional supplement or foodstuff referred to in [8] as an adjunct to the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.
• [14] Use according to [10], [11] or [12], where the food is a dietary food.
• [15] Use according to point [14], where the dietary food is a dietetic food for special medical purposes (supplementary balanced diet).

In one embodiment of the present invention, the stress, nutrition or endogenous disorder of serotonin metabolism is a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.

In one embodiment of the present invention, the use of the composition according to the invention as an adjunct to a stress, nutrition or endogenous disorder of serotonin metabolism is an addition to a stress, nutrition or endogenous serotonin deficiency in the CNS.

The present invention furthermore comprises the use of the composition according to the invention for the treatment of a state of mind which is characterized by a stress, nutrition or endogenous disorder of the serotonin metabolism, preferably characterized by a stress, nutrition or endogenous serotonin Deficiency in the CNS.

Persistent stress, an unbalanced diet or a specific individual predisposition may manifest as a disorder of serotonin metabolism.

Detailed description of the invention

The CNS-acting serotonin is synthesized in the CNS. Serotonin is made from the amino acid Synthesized tryptophan. Tryptophan, unlike serotonin, can cross the blood-brain barrier. The first prerequisite for sufficient biosynthesis of serotonin in the CNS is therefore an adequate supply of tryptophan.

The enzyme tryptophan hydroxylase catalyzes the hydroxylation of tryptophan to 5-hydroxytrypophan (5-HTP). 5-HTP is then converted to serotonin by HTP decarboxylase. The rate-limiting step in serotonin synthesis is the hydroxylation of tryptophan using tryptophan hydroxylase. Due to its high Km value (25 μM), tryptophan hydroxylase has only a poor affinity for its substrate and is only about half saturated at a tryptophan concentration in the CNS of only 10-30 μM tryptophan. This means that by increasing the tryptophan concentration up to twice the amount of serotonin can be produced.

However, since tryptophan is not naturally synthesized in the human body, tryptophan must be ingested with food. Thus, balance and happiness in humans are directly and fundamentally dependent on a sufficient supply of tryptophan. This becomes all the more evident from the aspect that only 1-3% of human-derived tryptophan is converted to serotonin. The serotonin of the CNS represents only a fraction of the total serotonin synthesis.

The need for adequate supply of tryptophan against the background of stress metabolism is reinforced. On the one hand stress counts as the cause of serotonin deficiency. Stress activates the hypothalamic-pituitary-adrenal axis (HHN axis, a positive feedback loop) and the serotonergic system in the brain, resulting in an increased cortisol concentration in the blood. When stress occurs, therefore, an increase in cortisol levels in the blood. Cortisol, however, promotes the breakdown of tryptophan ( Dinan et al., Brit. J. of Psychiatry 1994, 164: 365-371 ; Cowen et al., Brit. J. of Psychiatry, 2002, 180: 99-100 ). Feeding tryptophan-rich people exposed to stress situations not only leads to a better mood, but also to a cushioned cortisol response and thus to an improvement in the stress-related serotonin deficiency syndrome in the CNS.

Thus, an additional supply of tryptophan leads to positive effects on mood and cortisol response and thus ensures greater balance and stress resistance.

Tryptophan leads to an increase in the serotonin level. A nutritional (extrinsic) sufficient supply of tryptophan alone, however, is no guarantee for sufficient serotonin synthesis, because of the uptake of tryptophan to serotonin synthesis, a variety of physiological processes are to be considered, which decide on the rate of synthesis of serotonin. A product that offers only non-drug tryptophan in support of stress resistance, balance, and well-being would certainly be a sub-optimal solution to the underlying technical problem.

The composition according to the invention therefore has in addition to the tryptophan a number of other nutrients in concentrated form, which together stringently support serotonin synthesis in the CNS. The mode of action of these other nutrients in synergy with tryptophan for the stringent synthesis of CNS serotonin is explained below.

Glucose as a tryptophan transport aid in the CNS

Only a fraction of the dietary tryptophan is transported to the CNS for serotonin synthesis. For tryptophan to enter the CNS, it first has to cross the so-called blood-brain barrier. Here, however, tryptophan competes with some other amino acids, the large neutral amino acids (LNAAs), for the available transport sites. An increase in plasma tryptophan / LNAA ratio of 40-70% is required to stimulate central serotonin synthesis. However, glucose as a carbohydrate gives the tryptophan an indirect benefit. Because by a glucose intake insulin is released. However, insulin not only promotes the uptake of glucose into the cells, but also promotes protein synthesis and the transport of amino acids into the body's cells - with the exception of tryptophan. The effect described here for glucose can be achieved with all carbohydrates, which by their absorption cause an insulin secretion in analogy to the insulin secretion, which is caused by the uptake of glucose.

Thus, the amount of amino acids in the blood which compete with tryptophan for the transport sites at the blood-brain barrier is reduced by carbohydrates (glucose) or by the resulting insulin secretion, whereas the proportion of tryptophan in the blood remains constant and thus relative, compared to the competing amino acids, increases and thus provides for a facilitated transport of tryptophan into the CNS. The carbohydrate content present in the composition according to the invention corresponds to the average carbohydrate intake via food. This will be the Glucose levels are not raised unnecessarily, but a percentage sufficient supply of glucose is guaranteed. With tryptophan and a carbohydrate source, the composition according to the invention thus ensures two essential prerequisites for effective serotonin synthesis in the CNS.

After entering the CNS, tryptophan must first be enzymatically converted to 5-hydroxytryptophan before it can be converted to serotonin by hydroxytryptophan decarboxylase. An ineffective conversion of tryptophan to hydroxytryptophan leads to degradation of tryptophan and the like. a. to niacin and is thus lost to the synthesis of serotonin. It is therefore important to ensure the effective conversion of tryptophan to hydroxytryptophan. This ensures the composition according to the invention by the following nutrients:

Biopterin (tetrahydroxybiopterin)

Tetrahydroxybiopterin is a co-factor in the synthesis of serotonin and converts tryptophan by hydroxylation into 5-hydroxytryptophan. In the human organism, tetrahydroxybiopterin is synthesized from guanosine triphosphate (GTP) and is therefore not an essential nutrient. However, a relative undersupply of GTP can lead to insufficient supply of biopterin. Therefore, the composition according to the invention comprises royal jelly, which is known to contain a high proportion of biopterin ( Butenandt and Rembold, Hoppe-Seyler's Zeitschr. F. Physiol. Chem., 1958, 311, p. 79 ).

Vitamin B12 and Folic Acid: Indirect Helpers

Vitamin B12 is u. a. responsible for the synthesis of the bases adenine, guanine, cytosine and thymine, and thus for the synthesis of GTP, the biological precursor of biopterin. In addition to the biopterin from royal jelly, the addition of vitamin B12 additionally ensures that a sufficient concentration of biopterin is present in the CNS. Another reason for the use of vitamin B12 and also for the use of folic acid is to be seen in the fact that an association between a deficiency of tryptophan and a disorder of methionine / folate metabolism was observed, which is due to a reduced degradation of homocysteine is due. In these cases, a correspondingly high homocysteine level was found. The addition of vitamin B12 and folic acid, which are elementary in the breakdown of homocysteine, is a targeted and stringent intervention in this way.

iron

Not only does iron play a crucial role in the transport of oxygen in the human body as a component of hemoglobin, it is also found to be a co-factor in the active site of tryptophan hydroxylase and is therefore essential for the introduction of the hydroxy group on tryptophan to form 5 hydroxytryptophan.

Ascorbic acid (vitamin C)

Vitamin C fulfills a number of different functions in the human organism, which are just as necessary for collagen synthesis as its radical scavenging function. However, the composition of the present invention includes ascorbic acid to aid in the uptake of iron from the gastrointestinal tract, since iron is effectively taken up into the blood only in the presence of vitamin C. A second reason for the use of ascorbic acid is that it promotes the breakdown of tyrosine, the biological precursor of all catecholamines. As already mentioned, the composition according to the invention is intended to support the serotonin pathway and not the catecholamine metabolic pathway. By using ascorbic acid, the serotonin pathway is targeted and stringently supported over the catecholamine pathway.

Niacin: Effective conversion of tryptophan to serotonin

At a too slow conversion of tryptophan to hydroxytryptophan tryptophan u. a. degraded to niacin and is lost in this way for serotonin biosynthesis. Sufficient supply of niacin prevents the breakdown of tryptophan, which makes more tryptophan available for the synthesis of serotonin. The amount of niacin defined in the composition of the present invention provides sufficient saturation of the pathway for the degradation of tryptophan to niacin.

All o. G. Nutrients support the conversion of tryptophan to 5-hydroxytryptohan (5-HTP) by the enzyme tryptophan hydroxylase. 5-Hydroxytryptophan, in contrast to tryptophan, is converted extremely effectively by the enzyme hydroxytryptophan decarboxylase.

Pyridoxal phosphate (Vitamin B6)

For the conversion of 5-hydroxytryptophan to serotonin, the hydroxytryptophan decarboxylase is responsible. It requires pyridoxal phosphate for its enzymatic reaction. A lack of vitamin B6 also inhibits the activity of Tryptophan hydroxylase, thereby reducing serotonin synthesis. Thus, the composition of the invention comprises pyridoxine to ensure adequate supply of pyridoxal phosphate.

magnesium

Like a deficiency of vitamin B6, a magnesium deficiency leads to the inhibition of tryptophan hydroxylase. To further stringently support the successful metabolism of tryptophan, the composition of the invention contains magnesium.

Hydroxytryptophan is able to cross the blood-brain barrier. However, the composition according to the invention comprises tryptophan and not 5-hydroxytryptophan and the like. a. for the following reasons: Firstly, in the CNS tryptophan is converted into serotonin only in serotonergic cells, since only they have the enzyme tryptophan hydroxylase necessary for conversion into 5-HTP. In contrast, 5-HTP is also converted into serotonin in catecholaminergic cells by a non-specific amino acid decarboxylase. As a result, it is not only removed from the serotonergic cells as substrate and is no longer available there for the required and useful serotonin synthesis, but exerts a negative influence on the catecholamine effect in catecholaminergic cells by competitive inhibition. Although, as already mentioned, the composition according to the invention is intended to support the serotonin metabolism in serotonergic cells in a targeted and stringent manner, but this should be done without an artificial, d. H. unnatural, affecting the catecholamine metabolism happen. However, the use of 5-HTP would be such an artificial and unphysiological influence, since 5-HTP is found only in the lumen of serotonergic cells and not in the CSF. In other words, although the composition according to the invention, although purposefully and stringently promotes serotonin synthesis in the CNS and not the CNS catecholamine synthesis, the catecholamine synthesis should remain largely unaffected, as well as properties such as curiosity, alertness and a certain level of agitation associated with the Catecholamine effect, for which well-being and happiness are not completely irrelevant. For the stringent promotion of CNS serotonin synthesis, both a strengthening and a weakening of the natural catecholamine metabolism by the administration of 5-HTP would be counterproductive.

Second, 5-HTP is converted into serotonin almost directly and with little control, leaving serotonergic cells far less scope to convert tryptophan into serotonin as part of their natural metabolism. Because the composition of the invention creates the conditions for a natural serotonin synthesis and should not enforce brain doping in the strict sense. In addition, the serotonergic effects of 5-HTP in catecholaminergic cells are difficult to assess.

The composition according to the invention is therefore characterized in that the synergistic effect of tryptophan and the other nutrients described above in concentrated form promotes and promotes serotonin synthesis in the CNS. Thus, the composition of the present invention naturally provides for ensuring or even enhancing well-being, balance and stress resistance.

In one embodiment of the present invention, the stress, nutrition or endogenous disorder of serotonin metabolism is a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.

In one embodiment of the present invention, the use of the composition according to the invention as an adjunct to a stress, nutrition or endogenous disorder of serotonin metabolism is an addition to a stress, nutrition or endogenous serotonin deficiency in the CNS.

• (a) Tryptophan: 405–495 mg;
• (b) Niacin (Vitamin B3): 27–33 mg;
• (c) Pyridoxin (Vitamin B6): 18–22 mg;
• (d) Folsäure (Vitamin B9): 720–880 μg;
• (e) Cyanocobalamin (Vitamin B12): 8,1–9,9 μg;
• (f) Ascorbinsäure: 90–110 mg;
• (g) Magnesium: 90–110 mg;
• (h) Eisen(II): 2,7–3,3 mg;
• (i) Kohlehydrate, vorzugsweise Glukose (Dextrose): 13,1–16,1 g; und
• (j) Gelee Royal: 270–330 mg.

In a preferred embodiment, the composition according to the invention comprises per 30 ml of aqueous solution:

• (a) tryptophan: 405-495 mg;
• (b) Niacin (Vitamin B3): 27-33 mg;
• (c) pyridoxine (vitamin B6): 18-22 mg;
• (d) folic acid (vitamin B9): 720-880 μg;
• (e) cyanocobalamin (vitamin B12): 8.1-9.9 μg;
• (f) ascorbic acid: 90-110 mg;
• (g) Magnesium: 90-110 mg;
• (h) iron (II): 2.7-3.3 mg;
• (i) carbohydrates, preferably glucose (dextrose): 13.1-16.1 g; and
• (j) royal jelly: 270-330 mg.

• (k) Koffein: 36–44 mg; und/oder
• (l) Zink: 9–11 mg.

This preferred embodiment may further comprise per 30 ml of aqueous solution:

• (k) caffeine: 36-44 mg; and or
• (l) Zinc: 9-11 mg.

• (a) Tryptophan: 450 mg
• (b) Niacin (Vitamin B3): 30 mg
• (c) Pyridoxin (Vitamin B6): 20 mg
• (d) Folsäure (Vitamin B9): 800 μg
• (e) Cyanocobalamin (Vitamin B12): 9 μg
• (f) Ascorbinsäure: 100 mg
• (g) Magnesium: 100 mg;
• (h) Eisen(II): 3 mg;
• (i) Kohlehydrate, vorzugsweise Glukose (Dextrose): 14,6 g; und
• (j) Gelee Royal: 300 mg.

In a particularly preferred embodiment, the composition according to the invention comprises per 30 ml of aqueous solution:

• (a) Tryptophan: 450 mg
• (b) Niacin (Vitamin B3): 30 mg
• (c) pyridoxine (vitamin B6): 20 mg
• (d) folic acid (vitamin B9): 800 μg
• (c) cyanocobalamin (vitamin B12): 9 μg
• (f) ascorbic acid: 100 mg
• (g) Magnesium: 100 mg;
• (h) iron (II): 3 mg;
• (i) carbohydrates, preferably glucose (dextrose): 14.6 g; and
• (j) royal jelly: 300 mg.

• (k) Koffein: 40 mg; und/oder
• (l) Zink: 10 mg.

This particularly preferred embodiment may further comprise per 30 ml of aqueous solution:

• (k) caffeine: 40 mg; and or
• (l) Zinc: 10 mg.

The average person skilled in the art is able to calculate those amounts corresponding to those per 1 ml of aqueous solution on the basis of the amounts stated per 30 ml of aqueous solution.

• (a) Tryptophan: 1–2 Gew.-% (Einwaagespektrum 300–600 mg);
• (b) Niacin (Vitamin B3): 0,05–0,15 Gew.-% (Einwaagespektrum 15–45 mg);
• (c) Pyridoxin (Vitamin B6): 0,034–0,1 Gew.-% (Einwaagespektrum 10–30 mg);
• (d) Folsäure (Vitamin B9): 0,0013–0,004 Gew.-% (Einwaagespektrum 400–1200 μg);
• (e) Cyanocobalamin (Vitamin B12): 0,00001–0,00005 Gew.-% (Einwaagespektrum 5–15 μg);
• (f) Ascorbinsäure: 0,17–0,67 Gew.-% (Einwaagespektrum 50–200 mg);
• (g) Magnesium: 0,17–0,67 Gew.-% (Einwaagespektrum 50–200 mg);
• (h) Eisen(II): 0,0067–0,017 Gew.-% (Einwaagespektrum 2–5 mg);
• (i) Kohlehydrate: 33–66 Gew.-% (Einwaagespektrum 10–20 g); und
• (j) Gelee Royal: 0,34–1,67 Gew.-% (Einwaagespektrum 100–500 mg).

In a further embodiment, the composition according to the invention comprises per sample:

• (a) tryptophan: 1-2% by weight (weighing spectrum 300-600 mg);
• (b) niacin (vitamin B3): 0.05-0.15% by weight (weighing spectrum 15-45 mg);
• (c) pyridoxine (vitamin B6): 0.034-0.1% by weight (weighing spectrum 10-30 mg);
• (d) folic acid (vitamin B9): 0.0013-0.004% by weight (weighing spectrum 400-1200 μg);
• (e) cyanocobalamin (vitamin B12): 0.00001-0.00005% by weight (weighing spectrum 5-15 μg);
• (f) ascorbic acid: 0.17-0.67% by weight (50-200 mg).
• (g) Magnesium: 0.17-0.67% by weight (50-200 mg).
• (h) iron (II): 0.0067-0.017% by weight (weighing spectrum 2-5 mg);
• (i) carbohydrates: 33-66% by weight (10-20 g weighing spectrum); and
• (j) royal jelly: 0.34-1.67% by weight (100-500 mg weighing spectrum).

• (k) Koffein: 0,067–0,27 Gew.-% (Einwaagespektrum 20–80 mg); und/oder
• (l) Zink: 0,017–0,067 Gew.-% (Einwaagespektrum 5–20 mg).

This preferred embodiment may further comprise per sample:

• (k) caffeine: 0.067-0.27% by weight (weighing spectrum 20-80 mg); and or
• (I) Zinc: 0.017-0.067% by weight (weighing spectrum 5-20 mg).

• (a) Tryptophan: 1,35–1,65 Gew.-% (Einwaagespektrum 405–495 mg);
• (b) Niacin (Vitamin B3): 0,09–0,11 Gew.-% (Einwaagespektrum 27–33 mg);
• (c) Pyridoxin (Vitamin B6): 0,06–0,073 Gew.-% (Einwaagespektrum 18–22 mg);
• (d) Folsäure (Vitamin B9): 0,0024–0,0029 Gew.-% (Einwaagespektrum 720–880 μg);
• (e) Cyanocobalamin (Vitamin B12): 0,000027–0,000033 Gew.-% (Einwaagespektrum 8,1–9,9 μg);
• (f) Ascorbinsäure: 0,3–0,36 Gew.-% (Einwaagespektrum 90–110 mg);
• (g) Magnesium: 0,3–0,36 Gew.-% (Einwaagespektrum 90–110 mg);
• (h) Eisen(II): 0,009–0,011 Gew.-% (Einwaagespektrum 2,7–3,3 mg);
• (i) Kohlehydrate, vorzugsweise Glukose (Dextrose): 44–54 Gew.-% (Einwaagespektrum 13,1–16,1 g); und
• (j) Gelee Royal: 0,09–1,1 Gew.-% (Einwaagespektrum 270–330 mg).

In a preferred embodiment, the abovementioned composition per sample comprises:

• (a) tryptophan: 1.35-1.65 wt% (weighed spectrum 405-495 mg);
• (b) niacin (vitamin B3): 0.09-0.11% by weight (weighing spectrum 27-33 mg);
• (c) pyridoxine (vitamin B6): 0.06-0.073 wt% (weighing spectrum 18-22 mg);
• (d) folic acid (vitamin B9): 0.0024-0.0029% by weight (weighing spectrum 720-880 μg);
• (e) cyanocobalamin (vitamin B12): 0.000027-0.000033% by weight (weighing spectrum 8.1-9.9 μg);
• (f) ascorbic acid: 0.3-0.36% by weight (weighing spectrum 90-110 mg);
• (g) Magnesium: 0.3-0.36% by weight (weighing spectrum 90-110 mg);
• (h) iron (II): 0.009-0.011% by weight (weigh spectrum 2.7-3.3 mg);
• (i) carbohydrates, preferably glucose (dextrose): 44-54% by weight (weigh spectrum 13.1-16.1 g); and
• (j) royal jelly: 0.09-1.1% by weight (weighing spectrum 270-330 mg).

• (k) Koffein: 0,12–0,14 Gew.-% (Einwaagespektrum 36–44 mg); und/oder
• (l) Zink: 0,03–0,037 Gew.-% (Einwaagespektrum 9–11 mg).

This preferred embodiment may further comprise per sample:

• (k) caffeine: 0.12-0.14% by weight (weighed spectrum 36-44 mg); and or
• (I) Zinc: 0.03-0.037 wt .-% (weighing 9-11 mg).

• (a) Tryptophan: 1,5 Gew.-% (Einwaage 450 mg);
• (b) Niacin (Vitamin B3): 0,1 Gew.-% (Einwaage 30 mg);
• (c) Pyridoxin (Vitamin B6): 0,067 Gew.-% (Einwaage 20 mg);
• (d) Folsäure (Vitamin B9): 0,0027 Gew.-% (Einwaage 800 μg);
• (e) Cyanocobalamin (Vitamin B12): 0,00003 Gew.-% (Einwaage 9 μg);
• (f) Ascorbinsäure: 0,34 Gew.-% (Einwaage 100 mg);
• (g) Magnesium: 0,34 Gew.-% (Einwaage 100 mg);
• (h) Eisen(II): 0,01 Gew.-% (Einwaage 3 mg);
• (i) Kohlehydrate: 48 Gew.-% (Einwaage 14,6 g); und
• (j) Gelee Royal: 1 Gew.-% (Einwaage 300 mg).

In a particularly preferred embodiment, the abovementioned composition per weight comprises:

• (a) tryptophan: 1.5% by weight (weight 450 mg);
• (b) niacin (vitamin B3): 0.1% by weight (weight 30 mg);
• (c) pyridoxine (vitamin B6): 0.067% by weight (weight 20 mg);
• (d) folic acid (vitamin B9): 0.0027% by weight (weight 800 μg);
• (e) cyanocobalamin (vitamin B12): 0.00003% by weight (9 μg weight);
• (f) ascorbic acid: 0.34% by weight (100 mg weight);
• (g) magnesium: 0.34% by weight (100 mg weight);
• (h) iron (II): 0.01% by weight (weighed in 3 mg);
• (i) carbohydrates: 48% by weight (weight 14.6 g); and
• (j) royal jelly: 1% by weight (weight 300 mg).

• (k) Koffein: 0,13 Gew.-% (Einwaage 40 mg); und/oder
• (l) Zink: 0,034 Gew.-% (Einwaage 10 mg).

This particularly preferred embodiment may further comprise per sample:

• (k) caffeine: 0.13% by weight (weight 40 mg); and or
• (I) Zinc: 0.034% by weight (weighed in 10 mg).

The term royal jelly used here is synonymous with the terms used in the literature royal jelly, royal jelly and royal jelly. In the literature, royal jelly is also referred to as royal jelly juice or royal jelly juice. Royal jelly or royal jelly juice describes the juice secreted by the bees to raise the queen bees. Those skilled in the food art are well-known sources of royal jelly.

Pyridoxal phosphate is the metabolically active form of vitamin B6. Vitamin B6 (pyridoxine) is taken from the diet and converted in the body to its active form as a coenzyme pyridoxal-5-phosphate (PLP). In one embodiment, the composition of the invention may comprise pyridoxal phosphate instead of pyridoxine. In another embodiment, the composition of the invention may comprise pyridoxamine instead of pyridoxine.

In the context of the present invention, iron (II) (i.e., divalent iron) may be employed in various suitable formulations in the different embodiments of the composition of the invention. The person skilled in the art is familiar with suitable formulations of iron (II) for the various embodiments of the present invention. The use of iron (II) gluconate is preferred. In another embodiment, the use of an iron (II) hydroxide-sucrose complex is preferred. It is also possible to use mixed iron (II) formulations.

In one embodiment of the invention, the food comprising the composition of the invention is a dietary food. A dietetic food according to the present invention is preferably a dietary food for special medical purposes (balanced or complementary balanced diet). Supplementary balanced diets have a nutritional purpose and are therefore not medicinal products. While drugs are used to cure or alleviate disease, balanced diets have the purpose of nutritionally support and optimize the increased or specific need for nutrients. In addition, balanced diets may have the purpose of nutritionally supporting and optimizing the treatment of diseases. Supplementary balanced diets are therefore food. Dietetic foods for special medical purposes describes a category of foods for a particular diet that is intended for the dietary treatment of humans. Dietetic foods according to the present invention are not drugs. Its purpose is the increased or special nutritional needs of people for their dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, in particular a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS, a Modification of the normal diet, other foods for a particular diet or a combination of both are not enough.

In one embodiment, the dietary food of the present invention is a nutritional preparation. In one embodiment, the dietary food of the present invention is a nutritional supplement.

In one embodiment of the invention, the food comprising the composition of the invention is a nutritional physiological preparation. In one embodiment of the invention, the food comprising the composition of the invention is a nutritional supplement.

In a preferred embodiment, the food according to the present invention further comprises an aroma, preferably a fruit flavor. In a preferred embodiment, the dietetic food according to the present invention further comprises an aroma, preferably a fruit flavor. An aroma to be used in the present invention is a flavor for food. Such flavorings for foods are well known in the art and one skilled in the art can select a preferred flavor from them. Such flavors are liquid flavors or instant powder flavors. Preferred flavors in the context of the present invention are fruit flavors that are suitable for food. Particularly preferred is a flavor selected from the group consisting of: vanilla flavor, pineapple flavor, apple flavor, strawberry flavor, banana flavor, pear flavor, cola flavor, cappuccino flavor, hazelnut flavor, raspberry flavor Aroma, Cherry Flavor, Coconut Flavor, Tutti Frutti Flavor, Pastry Flavor, Chili Flavor, Lemon Flavor, Marzipan Flavor, Orange Flavor, Peach Flavor, and Chocolate Flavor. In one embodiment of the present invention, vanilla flavor is particularly preferred. In another embodiment of the present invention, tutti-frutti flavor is particularly preferred.

In one embodiment, the food according to the present invention is in the form of a loose or compacted powder. In one embodiment, the dietetic food according to the present invention is in the form of a loose or compacted powder. In one embodiment, the nutritional preparation according to the present invention is in the form of a loose or compacted powder. In one embodiment, the dietary supplement according to the present invention is in the form of a loose or compacted powder.

In one embodiment, the food comprising the composition according to the invention is characterized in that it is pasteurized. In one embodiment, the dietetic food comprising the composition of the invention is characterized by being pasteurized. In one embodiment, the beverage according to the present invention is characterized in that it is pasteurized. In one embodiment, the nutritional preparation according to the present invention characterized in that it is pasteurized. In one embodiment, the dietary supplement according to the present invention is characterized in that it is pasteurized.

In one embodiment, the present invention relates to a dietetic product and its use for treating a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.

In one embodiment, the present invention relates to a baby food comprising the composition according to the invention and its use for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS ,

In one embodiment, the present invention relates to a mineral dietary supplement comprising the composition according to the invention and its use for the treatment of a stress-, nutrition- or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS.

In one embodiment, the present invention relates to a dietetic beverage comprising the composition according to the invention and its use for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS ,

In one embodiment, the present invention relates to a lozenge comprising the composition according to the invention and its use for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS ,

In one embodiment, the present invention relates to a salt comprising the composition according to the invention and its use for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS ,

In one embodiment, the present invention relates to a vitamin preparation comprising the composition according to the invention and its use for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS ,

In one embodiment, the composition of the invention is part of a milk or milk product. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is a milk or a milk product. Accordingly, in one embodiment, a beverage according to the present invention is a milk or a milk product. Furthermore, in one embodiment, a nutritional preparation according to the present invention is a milk or a milk product. Furthermore, in one embodiment, a dietary supplement according to the present invention is a milk or a milk product.

In one embodiment, the composition according to the invention is part of a milk beverage with a predominant milk content. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is a milk predominant milk beverage. Accordingly, in one embodiment, a beverage according to the present invention is a predominantly milky milk drink. Furthermore, in one embodiment, a nutritional preparation according to the present invention is a milk beverage with a predominant milk content. Furthermore, in one embodiment, a dietary supplement according to the present invention is a milk beverage with a predominant milk content.

In one embodiment, the composition of the invention is part of a fruit snack. Accordingly, in one embodiment, a food or dietary food according to the present invention is in the form of a fruit snack. Accordingly, in one embodiment, a nutritional physiological Preparation according to the present invention in the form of a fruit snack. Furthermore, in one embodiment, a dietary supplement according to the present invention is in the form of a fruit snack.

In one embodiment, the composition of the invention is part of a jelly. Accordingly, in one embodiment, a food or dietary food according to the present invention is in the form of a jelly. Accordingly, in one embodiment, a nutritional preparation according to the present invention is in the form of a jelly. Furthermore, in one embodiment, a dietary supplement according to the present invention is in the form of a jelly.

In one embodiment, the composition of the invention is part of a beverage. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as a beverage. Such a beverage is preferably based on a milk or a milk product. In another preferred embodiment, a beverage according to the present invention is based on a predominantly milky milk drink. Furthermore, a preferred embodiment of a beverage according to the present invention is that the beverage is a beverage based on tea, coffee, coffee substitutes and / or cocoa.

The liquid embodiments according to the present invention may be packaged in bottles, cartons, cans, bags or the like. The powdered embodiments according to the present invention may be packaged in vacuum packs, cartons, cans, bags or the like. Suitable packaging is known to the person skilled in the art.

In one embodiment, the composition according to the invention is part of a fine bakery product or confectionery. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as a fine bakery product or confectionery.

In one embodiment, the composition according to the invention is a constituent of ice cream. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as an ice cream.

In one embodiment, the composition of the invention is part of a cereal snack. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as a corn snack.

In one embodiment, the composition of the invention is part of a confectionery, preferably chocolate. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as a sweet, preferably chocolate or candy.

In one embodiment, the composition of the invention is part of a non-alcoholic beverage. Accordingly, in one embodiment, a food or dietary food according to the present invention is present as an alcohol-free beverage.

In one embodiment, the composition according to the invention is part of a fruit drink or fruit juice. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is present as a fruit beverage or fruit juice.

In one embodiment, the composition according to the invention is part of an essence for the preparation of beverages. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is present as an essence for the preparation of beverages.

In one embodiment, the composition according to the invention is part of a syrup or other preparation for the preparation of beverages. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is present as a syrup or other preparation for the preparation of beverages.

In one embodiment, the composition according to the invention is part of an effervescent powder or an effervescent tablet for the preparation of beverages. Accordingly, in one embodiment, a food or dietary supplement according to the present invention is present as an effervescent tablet or effervescent tablet for the preparation of beverages.

The present invention comprises the use of the abovementioned embodiments of the composition according to the invention and of the foods or dietary foods according to the invention for the treatment of a stress, dietary or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS.

The uses described here are not limited to use in humans, but are equally suitable for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin Deficiency in the CNS, in any mammal, preferably in dogs, cats, pigs, cows and horses. Furthermore, the uses described herein are equally suitable for the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism, preferably a stress, nutrition or endogenous serotonin deficiency in the CNS, in birds.

When using the composition according to the invention for the treatment of a stress, nutrition or endogenous disorder of the serotonin metabolism, preferably a stress-, nutritionally or endogenously-caused serotonin deficiency in the CNS, the inclusion of the composition takes place in the embodiment of here described embodiments, preferably in oral form. In one embodiment, the recording can also be enteral.

For the preparation of the various embodiments of the present invention comprising the composition according to the invention, those skilled in the art can, if necessary, refer to auxiliaries known to him. In addition to antioxidants, dispersants, emulsifiers, defoamers, flavoring agents, preservatives, solubilizers or dyes may be used.

The composition according to the invention can be used to assist in the treatment of a stress, nutrition or endogenous disorder of the serotonin metabolism. Thus, the present invention also provides the use of the composition of the invention as an adjunct to the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.

One way to investigate the effect of tryptophan deficiency is acute tryptophan handover. The subjects are given a special amino acid mix that does not contain tryptophan. Within 5-6 hours there is a maximum lack of tryptophan in the blood plasma and the transport of tryptophan through the blood-brain barrier is reduced. This results in a significant decrease in serotonin synthesis in the brain.

example 1

• (a) Tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) Pyridoxin (Vitamin B6): 20 mg;
• (d) Folsäure (Vitamin B9): 800 μg;
• (e) Cyanocobalamin (Vitamin B12): 9 μg;
• (f) Ascorbinsäure: 100 mg;
• (g) Magnesium: 100 mg;
• (h) Eisen(II): 3 mg;
• (i) Kohlehydrate: 14,6 g; und
• (j) Gelee Royal: 300 mg.

A beverage having a volume of 30 ml comprising the composition shown below was prepared:

• (a) tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) pyridoxine (vitamin B6): 20 mg;
• (d) folic acid (vitamin B9): 800 μg;
• (e) cyanocobalamin (vitamin B12): 9 μg;
• (f) ascorbic acid: 100 mg;
• (g) Magnesium: 100 mg;
• (h) iron (II): 3 mg;
• (i) carbohydrates: 14.6 g; and
• (j) royal jelly: 300 mg.

This beverage can be used for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.

Example 2

• (a) Tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) Pyridoxin (Vitamin B6): 20 mg;
• (d) Folsäure (Vitamin B9): 800 μg;
• (e) Cyanocobalamin (Vitamin B12): 9 μg;
• (f) Ascorbinsäure: 100 mg;
• (g) Magnesium: 100 mg;
• (h) Eisen(II): 3 mg;
• (i) Kohlehydrate: 14,6 g;
• (j) Gelee Royal: 300 mg;
• (k) Koffein: 40 mg; und
• (l) Zink: 10 mg.

A beverage having a volume of 30 ml comprising the composition shown below was prepared:

• (a) tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) pyridoxine (vitamin B6): 20 mg;
• (d) folic acid (vitamin B9): 800 μg;
• (e) cyanocobalamin (vitamin B12): 9 μg;
• (f) ascorbic acid: 100 mg;
• (g) Magnesium: 100 mg;
• (h) iron (II): 3 mg;
• (i) carbohydrates: 14.6 g;
• (j) royal jelly: 300 mg;
• (k) caffeine: 40 mg; and
• (l) Zinc: 10 mg.

This beverage can be used for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.

Example 3

• (a) Tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) Pyridoxin (Vitamin B6): 20 mg;
• (d) Folsäure (Vitamin B9): 800 μg;
• (e) Cyanocobalamin (Vitamin B12): 9 μg;
• (f) Ascorbinsäure: 100 mg;
• (g) Magnesium: 100 mg;
• (h) Eisen(II): 3 mg;
• (i) Kohlehydrate: 14,6 g;
• (j) Gelee Royal: 300 mg; und
• (k) Zink: 10 mg.

A beverage having a volume of 30 ml comprising the composition shown below was prepared:

• (a) tryptophan: 450 mg;
• (b) Niacin (Vitamin B3): 30 mg;
• (c) pyridoxine (vitamin B6): 20 mg;
• (d) folic acid (vitamin B9): 800 μg;
• (e) cyanocobalamin (vitamin B12): 9 μg;
• (f) ascorbic acid: 100 mg;
• (g) Magnesium: 100 mg;
• (h) iron (II): 3 mg;
• (i) carbohydrates: 14.6 g;
• (j) royal jelly: 300 mg; and
• (k) zinc: 10 mg.

This beverage can be used for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited non-patent literature

• DAK, (2009), Doping in the Office, www.presse.dak.de [0005]
• Dinan et al., Brit. J. of Psychiatry 1994, 164: 365-371 [0018]
• Cowen et al., Brit. J. of Psychiatry, 2002, 180: 99-100 [0018]
• Butenandt and Rembold, Hoppe-Seyler's Zeitschr. F. Physiol. Chem., 1958, 311, p. 79 [0025]

Claims (10)

Composition comprising per 30 ml of aqueous solution: (a) tryptophan: 300-600 mg; (b) Niacin (Vitamin B3): 15-45 mg; (c) pyridoxine (vitamin B6): 10-30 mg; (d) folic acid (vitamin B9): 400-1200 μg; (e) cyanocobalamin (vitamin B12): 5-15 μg; (f) ascorbic acid: 50-200 mg; (g) magnesium: 50-200 mg; (h) iron (II): 2-5 mg; (i) carbohydrates: 10-20 g; and (j) royal jelly: 100-500 mg. A composition according to claim 1, further comprising per 30 ml of aqueous solution: (k) caffeine: 20-80 mg; and or (I) Zinc: 5-20 mg. A composition according to claim 1 or 2, wherein the carbohydrates are selected from the group consisting of monosaccharides, preferably glucose, fructose, galactose, xylose, and ribose; Glucose polymers; Glucose syrup; Sugar alcohols; Malto-dextrins; mannose; Fructose syrup; Corn syrup; maltose; sucrose; Glucose-containing disaccharides which are not maltose and sucrose, preferably a disaccharide selected from the group consisting of lactose, palatinose, trehalose, leucrose and isomaltose; Glucose-containing oligosaccharides; and glucose-containing polysaccharides. A formulation comprising the composition according to any one of claims 1, 2 or 3. Use of the composition according to one of claims 1 to 3 or the formulation according to claim 4 for the dietary treatment of a stress, nutrition or endogenous disorder of serotonin metabolism. Use according to claim 5, wherein the stress, nutrition or endogenous disorder of serotonin metabolism is a stress, nutrition or endogenous serotonin deficiency syndrome in the CNS. Use of the composition according to any one of claims 1 to 3 or the formulation according to claim 4 as an adjunct to the treatment of a stress, nutrition or endogenous disorder of serotonin metabolism. A beverage, nutritional preparation, food supplement or foodstuff comprising the composition according to any one of claims 1 to 3 or the formulation according to claim 4. A foodstuff according to claim 8, which is a dietetic food. Food according to claim 9, which is a dietetic food for special medical purposes (complementary balanced diet).